BACKGROUND: Few data are available on cutaneous leishmaniasis caused by dermotropic species in human immunodeficiency virus (HIV)-infected patients. OBJECTIVES: To describe nine cases of cutaneous leishmaniasis in HIV+ patients and to compare their clinical features and their response to treatment with those of HIV- patients with the forms of leishmaniasis commonly found in French Guiana. METHODS: A case-control study was carried out between July 1994 and December 2000 in French Guiana. We compared the following variables in nine HIV-infected patients with leishmaniasis and 27 matched controls: clinical type of leishmaniasis, number of lesions, presence of lymphangitis and adenopathy, the rate of recovery after treatment, and recurrence or reinfection. RESULTS: Eight of the HIV-infected patients had localized cutaneous leishmaniasis and one had mucocutaneous leishmaniasis. All of the controls had localized cutaneous leishmaniasis. Leishmania guyanensis was the only species isolated from HIV-infected subjects. HIV-Leishmania coinfected patients had a higher rate of recurrence or reinfection (P < 0.02) and a lower rate of recovery after one treatment cycle with pentamidine (P < 0.02) than did HIV- subjects. The CD4+ lymphocyte counts exceeded 200 mm(-3) in all HIV+ patients at the time of the diagnosis with leishmaniasis. CONCLUSIONS: In French Guiana, cutaneous leishmaniasis in moderately immunosuppressed HIV-infected subjects (> 200 CD4+ T cells mm(-3)) is characterized by a higher rate of recurrence or reinfection and is more difficult to treat than that in HIV- subjects.
BACKGROUND: Few data are available on cutaneous leishmaniasis caused by dermotropic species in human immunodeficiency virus (HIV)-infectedpatients. OBJECTIVES: To describe nine cases of cutaneous leishmaniasis in HIV+ patients and to compare their clinical features and their response to treatment with those of HIV- patients with the forms of leishmaniasis commonly found in French Guiana. METHODS: A case-control study was carried out between July 1994 and December 2000 in French Guiana. We compared the following variables in nine HIV-infectedpatients with leishmaniasis and 27 matched controls: clinical type of leishmaniasis, number of lesions, presence of lymphangitis and adenopathy, the rate of recovery after treatment, and recurrence or reinfection. RESULTS: Eight of the HIV-infectedpatients had localized cutaneous leishmaniasis and one had mucocutaneous leishmaniasis. All of the controls had localized cutaneous leishmaniasis. Leishmania guyanensis was the only species isolated from HIV-infected subjects. HIV-Leishmania coinfectedpatients had a higher rate of recurrence or reinfection (P < 0.02) and a lower rate of recovery after one treatment cycle with pentamidine (P < 0.02) than did HIV- subjects. The CD4+ lymphocyte counts exceeded 200 mm(-3) in all HIV+ patients at the time of the diagnosis with leishmaniasis. CONCLUSIONS: In French Guiana, cutaneous leishmaniasis in moderately immunosuppressed HIV-infected subjects (> 200 CD4+ T cells mm(-3)) is characterized by a higher rate of recurrence or reinfection and is more difficult to treat than that in HIV- subjects.
Authors: Manuel Calvopina; Cristina Aguirre; William Cevallos; Alberto Castillo; Ibrahim Abbasi; Alon Warburg Journal: Am J Trop Med Hyg Date: 2017-02-13 Impact factor: 2.345
Authors: Erika B Muñoz; Stephanie Santander; Patricio Rojas-Silva; Paul A Cardenas; Marco Fornasini; Sara C Cifuentes; Daniela Salvador; Manuel E Baldeón Journal: Am J Trop Med Hyg Date: 2016-08-01 Impact factor: 2.345
Authors: Jorge Augusto O Guerra; Leíla I R C Coelho; Flávio R Pereira; André M Siqueira; Rogério L Ribeiro; Thiago Miranda L Almeida; Marcus Vinícius G Lacerda; Maria das Graças V Barbosa; Sinésio Talhari Journal: Am J Trop Med Hyg Date: 2011-09 Impact factor: 2.345
Authors: Joanna R Santos-Oliveira; Carmem B W Giacoia-Gripp; Priscilla Alexandrino de Oliveira; Valdir S Amato; Jose Ângelo L Lindoso; Hiro Goto; Manoel P Oliveira-Neto; Marise S Mattos; Beatriz Grinsztejn; Mariza G Morgado; Alda M Da-Cruz Journal: BMC Infect Dis Date: 2010-12-20 Impact factor: 3.090